Immune cell-derived membrane nanovesicles: A promethean fire for autoimmune disease therapy through immune cell mimicry
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Autoimmune diseases (AIDs) constitute a heterogeneous group of disorders characterized by immune dysregulation, loss of self-tolerance, and chronic inflammation, which leads to tissue damage and organ dysfunction. Current therapies for AIDs are often limited by their lack of specificity, systemic side effects, and insufficient restoration of immune tolerance. Recent advances in nanotechnology and bioengineering have introduced immune and associated cell-derived membrane vesicles (IACMVs) as a promising therapeutic platform. Derived from macrophages, dendritic cells, neutrophils, platelets, or red blood cells, IACMVs inherit key surface proteins and receptors from their parent cells, conferring endogenous biocompatibility, inflammation-specific targeting, and intrinsic immunomodulatory capabilities. These vesicles can be engineered to carry therapeutic cargoes (e.g., peptide inhibitors, nucleic acids) or modified with surface ligands to enhance disease-site specificity, making them versatile tools for specific immunomodulation. This review provides a comprehensive overview of IACMVs, focusing on their preparation techniques, functional mechanisms, and therapeutic applications in prototypical AIDs such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), autoimmune hemolytic anemia (AIHA), type 1 diabetes (T1D), multiple sclerosis (MS), and autoimmune myocarditis (AM). We highlight translational challenges, including production scalability, membrane integrity, immunogenicity, and cargo-loading efficiency, that must be addressed to advance clinical translation. Finally, we discuss future directions for optimizing IACMVs as next-generation, safe, and targeted immunotherapeutic platforms for AIDs.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Immune cell-derived membrane nanovesicles: A promethean fire for autoimmune disease therapy through immune cell mimicry
- Date Crossref
- 01/12/2026
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Xiamen University Department of Rheumatology and Clinical Immunology pays non établi dans la noticeUniversité ou école supérieure
-
First Affiliated Hospital of Xiamen University pays non établi dans la noticeÉtablissement de santé
-
Xiamen Blood Center pays non établi dans la noticeÉtablissement de santé
-
School of Pharmaceutical Sciences State Key Laboratory of Vaccines for Infectious Diseases pays non établi dans la noticeUniversité ou école supérieure
-
Xiamen Key Laboratory of Rheumatology and Clinical Immunology pays non établi dans la noticeStructure de recherche
-
Xiamen Municipal Clinical Research Center for Immune Diseases pays non établi dans la noticeStructure de recherche
-
School of Life Sciences State Key Laboratory of Cellular Stress Biology pays non établi dans la noticeUniversité ou école supérieure
-
School of Public Health State Key Laboratory of Vaccines for Infectious Diseases pays non établi dans la noticeUniversité ou école supérieure
Department of Rheumatology and Clinical Immunology — Xiamen University, First Affiliated Hospital of Xiamen University et Xiamen Blood Center, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.